Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study

Lignende værker

• Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
  af: Sone, Hirohito, et al.
  Udgivet: (2019)
• The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
  af: Crane, James, et al.
  Udgivet: (2015)
• Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial
  af: Kawamori, Ryuzo, et al.
  Udgivet: (2018)
• Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial
  af: Kaku, Kohei, et al.
  Udgivet: (2018)
• Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial
  af: Shimada, Akira, et al.
  Udgivet: (2018)